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Most scientists would probably agree
that switching fields from time to
time is a good thing — for both
scientist and science. MacFarlane
Burnett and Neils Jerne, for example,
each brought concepts and
technology from microbiology to
immunology, and, as a consequence,
the clonal selection hypothesis, which
revolutionized immunology, was
born. Why then is field-switching not
more common? One reason is that
switching can be difficult.
The Wallace experience. I switched
to developmental neurobiology after
completing a PhD in immunology.
My new colleagues and, more
importantly, the Canadian Medical
Research Council and potential
postdoctoral supervisors were very
supportive, but the change was
difficult. The first problem was
deciding what I wanted to do and
where. As well as learning new
concepts, I wanted to learn new
techniques and approaches. In
retrospect, I was fortunate to find a
lab where the environment was
stimulating yet low-pressure.
The next problem was the
amount of new information, which
overwhelmed and, at times, almost
paralysed me. I had to keep
reminding myself that I was, in a
sense, learning a new language and
that I had to be patient — never one
of my strong points. One way that I
dealt with it was to attend
undergraduate lectures in my new
subject and to take excellent courses
at Cold Spring Harbor and Woods
Hole, which enabled me to establish
valuable contacts and gave me a
historical perspective of the field that
made reading easier.
Although switching fields has
been a challenge, it has also been
rewarding. I have learned new ways
of thinking about problems in
biology that complement the ways I
learned as a graduate student. It has
also emboldened me for future
ventures into new territory.
The Raff experience. I originally
trained as a clinical neurologist in
Boston and came to London to work
with Avrion Mitchison on
immunology at the National
Institute for Medical Research in
Mill Hill. I had not done research
before, so I had an intimidating
amount to learn. A medical training,
I discovered, is not optimal for doing
science. In medicine you mainly
look backward, comparing what you
are seeing now with what others
have seen and done before; in
science, you struggle to think
originally, which is rarely an effective
way to treat a patient. 
Switching to a new field can
invigorate and broaden a scientist
When Mitchison moved to University
College London in 1971, I moved
with him, to set up a developmental
neurobiology group. As an
immunologist, I had used antibodies
to cell-surface antigens to identify
and manipulate different classes of
lymphocytes, and I planned to use
the same strategy to study neural
cells. Remarkably, the Medical
Research Council (MRC) awarded us
a five-year Programme Grant to do it,
even though neither of us had done
any neurobiology before.
Kay Fields, a phage molecular
biologist, joined the project. She
used neural tumour cell lines to raise
antibodies that would distinguish
different types of normal neural cells,
but the strategy mostly failed. It was
years before she had an antiserum
that specifically recognized Schwann
cells in peripheral nerve cultures and
allowed us to do our first
neurobiology experiments.
These were difficult years. I knew
little neurobiology and found it hard
to learn more. I remained immersed
in immunology, and it was a struggle
to switch my interest. My scientific
friends were immunologists, I was
invited to talk only at immunology
meetings, and the young scientists
who applied to work with me wanted
to do immunology. It was five years
before we published our first
neurobiology paper, and even longer
before I managed to withdraw from
immunology completely to become a
full-time developmental
neurobiologist. I am not sure that I
could have made the transition if
Jeremy Brockes had not joined the
lab as a postdoc. Coming from the
Neurobiology Department at Harvard
Medical School, then the Mecca of
neurobiology, he played a crucial part
in my conversion. It was wonderful of
the MRC to continue to support us
through those lean years, and I
wonder if it, or any other funding
agency, would do the same today. The
antibody strategy eventually paid off
in developmental neurobiology, as in
so many other areas, especially after
the monoclonal antibody revolution.
These days, field-switching
usually occurs by chance: you knock
out a gene and part of the brain fails
to develop; to follow up such
findings you have to become a
developmental neurobiologist. In
this type of situation, switching is
relatively painless, as you start with
an interesting finding. Whether
chosen deliberately or triggered by a
chance observation, field switching
can bring rich rewards, both to the
scientists who do it and to the fields
they enter. Perhaps mentors and
funding agencies should encourage it
more than they do.
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